Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study. EHA 2022;Abstract S148.
Bataller A et al. Phase 1/2 study of oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. EHA 2023;Abstract S172.
Bewersdorf JP et al. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS). Blood Rev 2023;60:101072. Abstract
Brown JR et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388(4):319-32. Abstract
Buecklein VL et al. Trial in progress: An open-label phase II study of relatlimab with nivolumab in combination with 5-azacytidine for the treatment of patients with relapsed/refractory and elderly patients with newly diagnosed acute myeloid leukemia (AARON). Blood 2022;140(Supplement 1):3227-8. Abstract
Burgues JMB et al. Updated results of VEN-A-QUI study: A phase 1-2 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: Azacitidine or low-dose cytarabine with venetoclax and quizartinib. EHA 2023;Abstract S132.
Ciaurro V et al. Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in AML cells with MLL-rearranged and NPM1 mutation. Blood 2022;140(Supplement 1):3082-3. Abstract
Cuglievan B et al. Blastic plasmacytoid dendritic cell neoplasm: A comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 2023;37(9):1767-78. Abstract
Daver NG et al. A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML). ASCO 2023;Abstract TPS7073.
Daver NG et al. Trial in progress: A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML). EHA 2023;Abstract PB1888.
Daver NG et al. Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion. Am J Hematol 2023;98(8):1176-84. Abstract
Daver NG et al. Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: Phase Ib results. J Clin Oncol 2023;[Online ahead of print]. Abstract
Daver NG et al. TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: Biology, current therapy, and future directions. Cancer Discov 2022;12(11):2516-29. Abstract
Daver NG et al. Updated results of VEN-A-QUI study: A phase 1-2 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: Azacitidine or low-dose cytarabine with venetoclax and quirzatinib. EHA 2022;Abstract S132.
Della Porta MG et al. Luspatercept versus epoetin alfa for treatment (tx) of anemia in ESA-naive lower-risk myelodysplastic syndromes (LR-MDS) patients (pts) requiring rbc transfusions: Data from the phase 3 Commands study. EHA 2023;Abstract S102.
El Hussein S et al. Microsatellite instability assessment by immunohistochemistry in acute myeloid leukemia: A reappraisal and review of the literature. Clin Lymphoma Myeloma Leuk 2022;22(6):e386-91. Abstract S102.
Erba HP et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401(10388):1571-83. Abstract.
Figueroa M et al. Cigarette smoke exposure accelerates AML progression in FLT3-ITD models. Blood Adv 2023;[Online ahead of print]. Abstract.
Garcia-Manero G et al. Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)‑naive transfusion-dependent (TD) patients (pts) with lower‑risk myelodysplastic syndromes (LR-MDS). ASCO 2023;Abstract 7003.
Garcia-Manero G et al. ASTX727-03: Phase 1 study evaluating oral decitabine/cedazuridine (ASTX727) low-dose (LD) in lower-risk myelodysplastic syndromes (LR-MDS) patients. ASH 2022;Abstract 461.
Geissler K et al. Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized crossover phase 3 study of an oral hypomethylating agent, ASTX727 (DEC-C), compared to IV decitabine in AML patients. EHA 2022;Abstract P573.
Haddad F et al. Checkpoint inhibitors and other immune-based therapies in acute myeloid leukemia. Cancer J 2022;28(1):43-50. Abstract.
Knapper S et al. A randomised assessment of the sequential addition of the kinase inhibitor quizartinib to intensive chemotherapy in older acute myeloid leukaemia (AML) patients: Results from the NCRI AML18 trial. EHA 2023;Abstract S131.
Lachowiez CA et al. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 2022;97(11):1443-52. Abstract
Lee S-E et al. Immunologic predictors for clinical responses during immune checkpoint blockade in patients with myelodysplastic syndromes. Clin Cancer Res 2023;29(10):1938-51. Abstract
Perl AE et al. Outcomes in patients with FLT3-mutated relapsed/refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy. Transplant Cell Ther 2023;29(4):265.e1-10. Abstract
Perl AE et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 2022;139(23):3366-75. Abstract
Platzbecker U et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): Interim analysis of a phase 3, open-label, randomised controlled trial. Lancet 2023;402(10399):373-85. Abstract
Pratz KW et al. Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy: A phase IB study in patients with newly diagnosed AML. J Clin Oncol 2023;41(26):4236-46. Abstract
Rücker F et al. Next-generation sequencing-based measurable residual disease monitoring in acute myeloid leukemia with FLT3 internal tandem duplication treated with intensive chemotherapy plus midostaurin. EHA 2023;Abstract S135.
Sallman DA et al. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: Final results of a phase Ib study. J Clin Oncol 2023;41(15):2815-26. Abstract
Savona MR et al. Prolonged survival observed in 133 MDS patients treated with oral decitabine/cedazuridine. ICMS 2021;Abstract 48P.
Schlenk RF et al. Impact of allogeneic hematopoietic cell transplantation in first complete remission plus flt3 inhibition with quizartinib in acute myeloid leukemia with FLT3-ITD: Results from QuANTUM-First. EHA 2023;Abstract S137.
Senapati J et al. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol 2022;97(5):574-82. Abstract
Senapati J et al. Antibody-drug conjugates in myeloid leukemias. Cancer J 2022;28(6):454-61. Abstract
Shallis RM et al. Standardising acute myeloid leukaemia classification systems: A perspective from a panel of international experts. Lancet Haematol 2023;10(9):e767-76. Abstract
Shallis RM et al. TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. Cancer 2023;129(2):175-80. Abstract
Short NJ et al. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol 2019;10:2040620719827310. Abstract
Stahl M et al. An agenda to advance research in myelodysplastic syndromes: A TOP 10 priority list from the first international workshop in MDS. Blood Adv 2023;7(12):2709-14. Abstract
Stein AS et al. A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia. ASCO 2023;Abstract 7005.
Venugopal S et al. Clinical and molecular characterization of newly diagnosed IDH/TP53 co-mutated AML and impact of genomically sensitive treatment strategies. Blood 2022;140(Supplement 1):6328-30. Abstract
Yeh J et al. Efficacy and safety of gilteritinib vs. sorafenib as post-transplant maintenance in patients with FLT3-ITD acute myeloid leukemia. Blood 2022;140(Supplement 1):7686-8. Abstract
Yilmaz M et al. Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 2022;12(5):77. Abstract